Whitepapers
Scaling the healthcare wall: is Mexico an attractive market for high cost drug makers?
By Jack Rawson, Analyst Email: [email protected] At first glance Mexico presents a significant opportunity for drug manufacturers, with a large population of over 126 million,
Future-proofing 2019 plans: P4A’s 6 Orphan Drug, Cell & Gene Therapy trends to watch out for
2019 is expected to a strong year for the orphan drug industry with an expected 10% surge in sales growth. Contributing to this growth will
Rare Diseases: A New Purpose
How drug repurposing could help drive orphan drug access if pharma can accept the risks By Nader Murad, Senior Analyst Email: [email protected] The US National
Partners4Access Briefing: November 2018 update on the European Commission regulation proposal on health technology assessment
By Christina Poschen, Consultant Email: [email protected] Background Since 2004, the European Union’s centralised drug approval is in place, allowing manufacturers to submit just one application to
Innovative Access Agreements: A potential payer solution for Cell & Gene Therapies
A US and EU perspective By Daniele Severi Bruni & Sophie Schmitz What’s the idea? Payer concerns over increasing cost of therapies and uncertainty of
CAR-T Therapies, the future for cancer patients? A market access perspective
Chimeric Antigen Receptor T-cell (CAR-T) therapies, which use a patient’s own immune cells to fight cancer, are one of the most exciting breakthroughs in cancer
What does the new FDA accelerated regulatory pathway mean for gene therapies?
U.S. Food and Drug Administration (FDA) commissioner Scott Gottlieb has announced that the drug agency is developing a system by which innovative gene therapies could
Biopharma 2018 Success Kit: 11 months to go, 6 rare disease trends to watch!
For the rapidly developing orphan drug market, change is a constant. From new technologies to discussions over pricing, the estimated $137 billion market will witness
ICER finds Roche’s Hemlibra cost-effective despite high price tag
Roche’s new haemophilia treatment, Hemlibra, is has a high estimated price tag of $482,000 for the first year of treatment and $448,000 for every subsequent
